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Message from the Director  
The third decade of the HIV/AIDS epidemic is a time to reflect on 
the successes of HIV/AIDS prevention—and there are many—and 
to plan for the future. Studies performed by CDC and others have 
scientifically proven that HIV/AIDS prevention interventions can 
protect people by helping them reduce the behaviors that put them 
at risk for HIV infection. These effective interventions are being 
disseminated through CDC’s programs, and many people have 
avoided HIV infection as a result of prevention efforts.  
Despite the availability of effective prevention interventions, CDC estimates that 
40,000 people—too many—become infected with HIV each year in the United 
States. Although this estimate has remained the same for the past decade, the 
epidemic has not. Advances in treatment are helping more and more HIV-infected 
people live healthier and longer lives. And with more people living with HIV than 
ever before, it is increasingly important that people know their HIV status so 
they can receive treatment for themselves and avoid transmitting their infection 
to others. Even the treatments themselves pose challenges, as they potentially 
encourage an attitude of complacency. And each new generation of young people 
presents an audience in need of new or reinforced HIV/AIDS prevention messages.
We hope that this booklet helps you better appreciate the HIV/AIDS prevention 
challenges of the third decade and CDC’s efforts to meet them. Its primary focus 
is the epidemic in the United States and the work of CDC’s Divisions of HIV/AIDS 
Prevention. Coverage of all HIV/AIDS prevention work at CDC would be too 
extensive for this booklet.
We begin in the past, with a brief history of accomplishments since 1981. Then we 
focus on the present: the current status of the epidemic in the United States and 
CDC’s responses. 
We conclude by looking into the future. CDC’s HIV Prevention Strategic Plan is 
the overarching force behind our approach to the third decade of HIV prevention. 
Advancing HIV Prevention: New Strategies for a Changing Epidemic is a new 
initiative specifically intended to reduce barriers to early diagnosis of HIV infection 
and increase access to quality medical care, treatment, and ongoing prevention 
services for people who are living with HIV. Finally, CDC continues to review and 
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improve its surveillance, research, and prevention programs to have a greater 
impact on the HIV epidemic. For example, CDC will be revising its guidance to 
better facilitate HIV screening in health care settings. It is also conducting state-
of-the-art prevention trials, using antiretroviral drugs to develop new methods 
to prevent transmission of HIV. Throughout the third decade of the HIV/AIDS 
epidemic, CDC will continue to adapt to changing trends to prevent new HIV 
infections and improve the quality of life for those living with HIV.
Robert S. Janssen, MD  
Director, Division of HIV/AIDS Prevention–Surveillance and Epidemiology
Acting Director, Division of HIV/AIDS Prevention–Intervention Research and 
Support
National Center for HIV, STD, and Tb Prevention
Coordinating Center for Infectious Diseases




About this document 
Abbreviations,	acronyms,	and	initialisms
The following are used commonly throughout the document. Those not listed here 
are explained at first mention on each page.
AIDS  acquired immune deficiency syndrome
CbOs  community-based organizations
CDC  Centers for Disease Control and Prevention
HAART highly active antiretroviral therapy
HIV  human immunodeficiency virus
IDUs  injection drug users
MSM  men who have sex with men
STD  sexually transmitted disease
Data 
The data presented in this document are estimates derived from HIV/AIDS 
surveillance data reported to CDC. The data are statistically adjusted for reporting 
delays and for the redistribution of cases initially reported without risk information.
Data from states that have required HIV reporting since 1994 are referred to as the 
25 states with long-standing HIV reporting. These 25 states are Alabama, Arizona, 
Arkansas, Colorado, Idaho, Indiana, Louisiana, Michigan, Minnesota, Mississippi, 
Missouri, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, 
South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, 
Wisconsin, and Wyoming. 
x
Mission Statements 
Division of HIV/AIDS	Prevention–Surveillance	and	Epidemiology  
Provide national leadership for HIV prevention research and surveillance and 
the development and testing of effective biomedical interventions to reduce HIV 
transmission and HIV disease progression in the United States and internationally. 
The purpose of these activities is to guide the development, implementation, and 
evaluation of evidence-based HIV prevention programs serving persons affected by, 
or at risk for, HIV infection.  
Division of HIV/AIDS Prevention–Intervention Research and Support 
Provide national leadership and support for HIV prevention research and the 
development, implementation, and evaluation of evidence-based HIV prevention 
programs serving persons affected by, or at risk for, HIV infection.   
one
The past 2 decades
How far haVE WE COME?
The magazine covers have been reprinted by permission with all rights reserved. 
Time: © 1986 Time Life Pictures/Getty Images. 
Newsweek: © 1986 Newsweek, Inc. 
People: © 1990 Time Inc. 
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One The Past 2 Decades
During the early 1980s, as many as 150,000 people became infected 
with HIV each year. by the early 1990s, this rate had dropped to 
approximately 40,000 each year, where it remains today.
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Advances in Prevention and Treatment
 Drastic reductions in mother-to-child HIV transmission
 New drug combinations to treat HIV and delay the onset of AIDS 
 Increased community involvement in HIV prevention efforts 
 better understanding of which communities are at high risk for 
HIV infection
 behavioral interventions shown to be effective through 
randomized, controlled clinical trials
Well-designed and well-delivered HIV prevention programs have 
contributed to safer behaviors and have helped reduce the number of 
new infections. 
Prevention effectiveness has been proven scientifically. Among those 
who have benefited are MSM, IDUs, heterosexual men and women 
at high risk, youth at high risk, and children born to HIV-infected 
mothers. These results reflect sustained, focused, and collaborative 
efforts among CbOs, federal agencies, foundations, prevention 
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reduce the 




How Far Have We Come?
Overall	Decline	in	AIDS Cases
AIDS cases have declined dramatically in certain populations and 
regions. New AIDS cases in the United States increased rapidly 
during the 1980s, peaked in the early 1990s, and then began to 
decline dramatically in 1996. The peak in 1993 was associated with 
expansion of the AIDS case definition. Subsequent declines are most 
likely the result of improved HIV treatment.
Declines	in	AIDS Cases in Certain Risk Groups
MSM
It has been estimated that during the mid 1980s, nearly 50% of 
MSM in some major urban gay communities in the United States 
were infected with HIV. Although MSM continue to account for the 
largest number of people for whom a diagnosis of AIDS is made each 
year, new AIDS cases in this population declined dramatically before 
stabilizing and then increasing slightly.
IDUs
During the 1980s, injection drug use was another major route for 
HIV transmission in the United States. After more than a decade 
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One
exchange programs, safer injection practices, peer support, street 
outreach, and counseling—new AIDS cases in IDUs declined.

















The estimated number of US children with AIDS declined 94% 
from 1992 (when the number of cases peaked) through 2003. This 
decline reflects the use of antiretroviral therapy to prevent HIV 
transmission from mother to child.
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How Far Have We Come? One
Declines	in	AIDS Cases in Geographic Regions
In most US regions, new AIDS cases were first observed to decline in 
1996. More recently, from 2002 through 2003, the number of AIDS 
cases increased in the Northeast, South, and Midwest and decreased 
in the West.  

















What Is the Magnitude?
The HIV/AIDS EpidemicTwo
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How Serious Is It? 
despite 
declines in new 
infections in 
the early 1990s, 
more people 
are living with 
hIv/aIds than 
ever before. 
The HIV/AIDS epidemic has taken a tremendous toll on people 
in the United States. From the beginning of the epidemic in 1981 
through 2003, an estimated 1.3–1.4 million people in this country 
have been infected with HIV/AIDS. Of these, about one third (more 
than 500,000) have died.
Despite declines in new infections in the early 1990s, more people 
are living with HIV/AIDS than ever before. CDC estimates that 
about 1 million people in the United States are living with HIV 
or AIDS.  About one quarter of these people are unaware of their 
infection, which puts them and others at risk. Those who do not 
know that they are infected cannot take advantage of treatment and 
may unknowingly transmit HIV to others. And even of the three 
quarters who know that they are HIV-infected, one third may not be 
receiving ongoing care. About half of all HIV-infected people may be 
untested, untreated, or both.
AIDS
New AIDS cases and deaths have declined dramatically since the 
beginning of the epidemic. However, this decline began to stabilize 
in 1999 and may not drop further unless new HIV infections also 
decrease or new treatments are developed. The decline in AIDS 
cases should not be confused with a decline in new HIV infections or 
an end to the epidemic. It can mean that fewer HIV infections are 
progressing to AIDS.  
HIV
New HIV infections have also declined but have 
remained stable for several years. At an estimated 
40,000 new HIV infections per year, this number is 
unacceptably high. It represents the spreading of the 
epidemic into new, vulnerable populations. 
Although effective treatment will ensure that fewer 
HIV infections progress to AIDS, it means that more 
and more people will be living with HIV, producing 
a wellspring of potential new infections. It is also important to 
note that treatment does not cure HIV infection. And no one knows 
TwoWhat Is the Magnitude?
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whether treatment may produce long-term adverse effects or 
whether the drugs will remain effective. These realities underscore 
the importance of tracking the epidemic and using scientifically 
proven prevention programs to protect the people who are most at 
risk. 
How Is It Changing?
The epidemic is changing in terms of how many people are living 
with HIV, where they are living, who is most vulnerable, and how 
we track the epidemic.
 More people are living with HIV. because of treatment 
advances, people with HIV are living longer. As a result, more 
people are living with HIV today than at any other time during 
the history of the epidemic.  Along with this growing population 
of HIV-infected persons, chances for transmission are increasing.
 The epidemic keeps moving. The HIV/AIDS epidemic varies 
considerably across the country, not only by region, but within 
regions and states, and even within communities. Currently (as 
well as for the past several years), many people with AIDS live in 
rural areas or small cities in the South.
o	
Racial and ethnic minorities. The epidemic has expanded 
from primarily affecting white people to primarily affecting 
people of color.
o	
Women. More than half of heterosexually acquired HIV 
infections occur in women.
o	 Youth. New generations are replacing those who benefited 
from early prevention strategies.
 Populations affected are changing. In addition to the 
groups who have been at highest risk since the beginning of the 
epidemic—MSM and IDUs—other groups are also at risk for 
HIV. 
 Tracking the epidemic is more complex. Early on, CDC 
tracked the epidemic by monitoring new AIDS cases. Today, 
trends in the epidemic are better reflected by new HIV infections, 
which are more difficult to track. New HIV infections cannot be 
measured directly because many newly infected people do not get 
tested and because a positive test result alone does not indicate 
whether the infection is recent.  
The epidemic 
is changing in 
terms of how 
many people 
are living with 
hIv, where 
they are living, 
who is most 
vulnerable, and 





















of people at 
high risk so that 
CdC can track 
the epidemic 
and direct hIv 
prevention 
funding to 
where it is 
needed the 
most.
CDC’S HIV/AIDS surveillance system is the nation’s source for key 
information used to track the epidemic. CDC funds and assists state 
and local health departments, which collect the information. Health 
departments in turn report their data to CDC so that information 
from around the country can be analyzed to determine who is being 
affected and why. 
The ultimate surveillance goal is a nationwide system that combines 
information on AIDS cases, new HIV infections, and behaviors and 
characteristics of people at high risk so that CDC can track the 
epidemic and direct HIV prevention funding to where it is needed 
the most.
Tracking AIDS Trends
During the 1980s, AIDS cases alone provided an adequate picture 
of HIV trends because the time between infection with HIV and 
progression to AIDS was predictable. This predictability, however, 
has diminished since 1996, when HAART became available. Access, 
adherence, and response to HAART affect whether or when HIV 
progresses to AIDS. Thus, trends in AIDS cases alone no longer 
accurately reflect trends in HIV infection. AIDS trends do, however, 
continue to provide important information about where care and 
treatment resources are most needed.  
Tracking HIV Trends 
by April 2004, all states had adopted some type of system for 
reporting HIV diagnoses to CDC. Tracking HIV trends is challenging 
and depends on several factors, such as how often people are tested, 
when during the course of their infection they are tested, whether 
and how test results are reported to health departments, and how 
case reports (with personal identifiers removed) are forwarded  
to CDC. 
A major advance has been the development of the serologic testing 
algorithm for recent HIV seroconversion (STARHS). STARHS 
is a way of analyzing HIV-positive blood samples to determine 
whether an HIV infection is recent or has been ongoing. In 2001, 
an expert panel agreed that STARHS is the best method available 
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for measuring new HIV infections. After funding 5 areas to pilot 
test this method, CDC has now funded a total of 34 areas to include 
STARHS in their HIV incidence surveillance activities. 
Monitoring HIV Risk Behavior 
behaviors are monitored with regard to risk taking, HIV testing, 
care seeking, and adhering to treatment for HIV. CDC obtains 
behavioral information from several different populations.  
General population 
Several federally supported surveys collect information about HIV-
related behaviors of the general population. They are conducted 
periodically so that trends can be evaluated. Here are a few 
examples.
 CDC conducts the behavioral Risk Factor Surveillance System, 
the National Survey of Family Growth, and the National Health 
Interview Study.  
 The National Opinion Research Center (University of Chicago) 
conducts the General Social Survey, with indirect support from 
CDC. 
 The Substance Abuse and Mental Health Services Administration 




People who are HIV-infected 
MMP (Morbidity Monitoring Project) is a new surveillance 
system designed to collect information from HIV/AIDS patients who 
received care from randomly selected HIV care providers.  In 2004, 
CDC awarded funds to 20 states and 6 cities for this project. MMP 
collects information about access to and use of HIV care, treatment, 
and prevention services and prevalence of behaviors that can result 
in HIV transmission and affect disease outcomes (like adherence to 
therapy). Information is collected from medical records and patient 
interviews. Patients are selected in a way that will make the data 
nationally representative for persons who are living with HIV/AIDS 
and receiving care.  Data for planning, evaluation, monitoring, and 
allocation of resources will be available by the 
end of 2006.
People who are at high risk for HIV
The NHBS (National HIV Behavioral 
Surveillance System), for populations at high 
risk, began in 2003. NHbS conducts surveys 
in cities with high levels of AIDS among 
MSM, IDUs, and heterosexuals at high risk to 
determine their risk behavior, testing behavior, 
and use of prevention services. In the first cycle, 
MSM were interviewed in 17 cities. The second cycle will interview 
IDUs in 25 cities.  In 2006, CDC will expand the system to include 
heterosexuals at high risk.   For states with medium and low 
levels of AIDS, CDC provides technical assistance and support for 
behavioral surveys among MSM at specified events, such as gay 
pride. 
HITS (HIV Testing Survey) primarily interviewed adults who 
were not HIV-infected but were at high risk for HIV infection. HITS 
collected information about what motivates people to get tested for 
HIV and what behaviors place people at risk for HIV. HITS was 
conducted in 24 states during 1995–2003. Data analyses from HITS 
are ongoing.




in CdC’s fight 
against hIv/aIds 
is hIv prevention 
programs. 
Monitoring	HIV	Counseling	and	Testing	Behavior 
The HIV Counseling and Testing System (CTS) has been used 
since 1989 to monitor CDC-funded HIV counseling and testing 
services. Through this system, each CDC-funded HIV counseling 
and testing episode is reported to CDC and includes information 
about demographics, self-reported behavior, and HIV test results. 
Data from this system are used to guide the development of HIV 
prevention programs in response to the needs of the community. 
beginning in 2005, CTS will be replaced by the Counseling, 
Testing, and Referral (CTR) module of the Program Evaluation 
and Monitoring System (PEMS). Data collected by CTR have 
been updated to include information on new testing technologies 
and client referrals to medical care and other services and to 
be consistent with other PEMS data collection and reporting 
requirements.
Prevention Programs 
The primary component in CDC’s fight against HIV/AIDS is HIV 
prevention programs. Programs consist of interventions intended to 
change risky behavior and improve the health of the people served. 
Interventions include encouraging early HIV diagnosis; delivering 
counseling, testing, and referral services; providing educational 
programs and materials; and training peers to be role models. They 
are delivered to individuals, groups, and communities in places such 
as storefronts, gay bars, health centers, housing communities, faith-
based organizations, and schools. Street outreach techniques such 
as using mobile testing vans, offering incentives for participation or 
referral, and recruiting peers are some of the ways to reach as many 
people as possible. 
CDC provides leadership, capacity building assistance, and funding 
for programs at the state, local, and community levels. CDC funding 
supports staffing, program infrastructure, implementation and 
evaluation of interventions. In many instances, CDC requires that 
those who receive funding for programs (grantees) have a proven 
track record of providing effective programs. CDC also strives to 
ensure that interventions meet local needs. Specifically, CDC asks 




is, they should meet the cultural needs, expectations, and values of 
the populations they serve. Community planning helps ensure that 
priorities for HIV prevention are determined locally with input from 
affected communities and that they are consistent with scientific 
findings about what interventions are most effective for decreasing 
HIV transmission.
Evaluation (to measure program effectiveness) is an important part 
of prevention programs. Programs funded by CDC are required 
to collect and submit evaluation data so that CDC can track and 
identify the most effective programs. CDC’s evaluation efforts take 
several forms.
 Evaluation guidance outlining the types of data each funded 
health department must collect from its grantees
 Regular reviews of each funded health department to evaluate 
effectiveness in community planning
 Ongoing reviews of funded CbOs  
In addition, CDC researches the effectiveness of HIV prevention 
interventions and the diffusion of these interventions. CDC’s 
Prevention Research Synthesis Project identifies interventions that 
have proven effective with various groups. The Replicating Effective 
Programs (REP) project takes proven interventions and packages 
them in a tool kit for distribution. CDC’s Diffusion of Effective 
behavioral Interventions (DEbI) project then looks at ways to get 
these effective interventions to a broader audience.
Health	Departments
CDC funds and works with 65 state, local, and territorial health 
departments to support prevention efforts and programs for 
people living with HIV and people at risk for HIV. All 65 health 
departments provide HIV counseling and testing services, which 
include referral and partner notification. A requirement for CDC 
funding is the development of a community planning process, which 
unites health departments and community members in developing 
an HIV prevention plan that reflects their local epidemic and guides 
HIV prevention efforts in their local area. Health departments also 
use CDC funds to support CbOs (indirect funding).
17
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Nongovernment Organizations
CDC supports community-based, faith-based, and other 
nongovernment organizations in building partnerships for HIV 
prevention. These efforts provide interventions for populations at 
high risk, including people of color, MSM, substance abusers, and 
correctional facility inmates. To help people living with HIV/AIDS 
access prevention and treatment services, these organizations also 
provide HIV counseling and testing services and programs.
Public-Private	Partnerships
CDC works with business and labor groups to enhance the health, 
productivity, and well-being of workers and their families living 
with, affected by, or at risk for HIV/AIDS. The business Responds 
to AIDS (bRTA) and Labor Responds to AIDS (LRTA) programs 
are worldwide public-private partnerships that serve as a resource 
to business and labor on a full range of HIV/AIDS issues. These 
partnerships set up workplace and related programs that combat 
complacency and stigma and support community activism, 
volunteerism, and corporate philanthropy.
Another CDC partnership is AIDS: Act Now! This public-private 
effort has a council of 50 members from business, faith-based, 
public health, and HIV communities, and the media. In addition, 
5 alliances focus on issues such as leadership, youth, media, HIV 
testing and clinical care, and Internet technology. In total, CDC 
has obtained the support of more than 100 partners who volunteer 
their time to explore how they can use their resources, influence, 
and outreach capabilities to enhance HIV prevention efforts in 
communities most affected by HIV and AIDS. As communities 
of color disproportionately bear the effects of the epidemic, most 
activities under AIDS: Act Now! are directed toward these groups.
Prevention Strategies 
Among CDC’s strategies for HIV prevention are
 providing up-to-date scientific information through guidelines
 promoting early diagnosis of HIV infection
 addressing the unique prevention needs of HIV-infected  persons 




deliver effective prevention programs that reduce risk for HIV 
transmission 
 increasing the quality of HIV prevention programs through 
evaluation
Guidelines
Guidelines are written recommendations for health care providers 
in the public and private sectors. They are developed after 
consultations with health care providers, public health officials, 
patient advocates, and policy experts. They are based on available 
scientific evidence; where evidence is incomplete, the “best practices” 
opinions of specialists in the field are used.  
Revised Guidelines for HIV Counseling, Testing, and Referral 
(2001)
Guidelines for HIV counseling, testing, and referral (CTR) were 
published in 1986 and revised in 1994. After a massive effort to 
review all current scientific evidence, obtain recommendations, and 
reach agreement on recommendations, CDC published the Revised 
Guidelines for HIV Counseling, Testing, and Referral in 2001. Using 
an evidence-based approach, these guidelines advise providers of 
voluntary HIV CTR how to improve the quality and delivery of HIV 
CTR. They underscore the importance of early knowledge of HIV 
status and of testing that is more accessible and available.
Revised Recommendations for HIV Screening of Pregnant Women 
In 1995, the US Public Health Service issued guidelines 
recommending universal counseling and voluntary HIV testing of 
all pregnant women and treatment for those infected to prevent 
mother-to-child HIV transmission. Subsequently, mother-to-child 
HIV transmission declined dramatically. In 2001, the Revised 
Recommendations for HIV Screening of Pregnant Women were 
published. These guidelines strengthen the recommendation that all 
pregnant women be tested for HIV as part of routine perinatal care, 
while preserving a woman’s right to make her own decisions about 
testing.
19
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Recommendations for Incorporating HIV Prevention into the 
Medical Care of Persons Living with HIV
In 2003, CDC, the Health Resources and Services Administration, 
the National Institutes of Health, and the HIV Medicine 
Association of the Infectious Diseases Society of America 
developed recommendations to help clinicians incorporate HIV 
prevention into the medical care of HIV-infected individuals. These 
recommendations include 
 screening for HIV transmission risk behaviors and sexually 
transmitted diseases
 providing behavioral risk-reduction messages in the office and 
referral for other prevention interventions and related services
 facilitating the notification and counseling of sex partners and 
needle-sharing partners
Procedural Guidance for Selected Strategies and Interventions 
for Community-based Organizations Funded Under Program 
Announcement 04064
The Procedural Guidance provides information to CbOs about the 
interventions that are allowable under Program Announcement 
04064.  It is available at www.cdc.gov/HIV/partners/pa04064_cbo.
htm.
HIV Prevention Community Planning Guidance 
This guidance, revised in July 2003, defines CDC’s expectations 
for health departments and HIV prevention community planning 
groups involved in HIV prevention community planning. These and 
other CDC recommendations and guidelines are available at www.
cdc.gov/HIV/pubs/guidelines.htm.
Advancing HIV Prevention: New Strategies for a Changing 
Epidemic 
Advancing HIV Prevention (AHP) is a combined effort of CDC and 
other agencies (government and nongovernment). It is designed 
to reduce barriers to early diagnosis of HIV infection and increase 
access to quality medical care, treatment, and ongoing prevention 
services for people living with HIV. It emphasizes the use of public 
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and spread of disease, such as appropriate routine HIV testing; 
identification of new cases; partner counseling, testing, and referral 
services; and increased availability of treatment and prevention 
services for HIV-infected persons and their partners.  AHP is 
described in more detail in Section 5, The Future.
Other CDC-funded projects help communities improve referrals to 
care and prevention services. 
 Project HEART (Helping Enhance Adherence to 
Antiretroviral Therapy), a clinic-based behavioral intervention 
for patients who have not previously received HAART
 Partnership for Health (Safer Sex and Adherence 
Intervention for HIV Outpatient Clinics), an intervention 
encouraging health care providers to promote safer sex and 
adherence to therapy
 INSPIRE (Interventions for HIV-Positive Intravenous 
Drug Users: Research and Evaluation), a behavioral 
intervention to help IDUs decrease their  risk for HIV, increase 
access to care, and increase adherance to HAART
Capacity	Building	
CDC recognizes that organizations funded to conduct HIV 
prevention, such as health departments and CbOs, often 
face challenges to meeting  the increased prevention needs of 
populations at high risk for HIV and other sexually transmitted 
infections.  Examples of these challenges are the need 
 to diversify the funding base to help sustain prevention services
 for effective behavioral interventions that are based on science 
and are culturally competent
 for competent staff
 for effective strategies to link HIV-negative and HIV-infected 
persons at high risk to services (testing, prevention, and care)
The goal of CDC’s HIV prevention capacity building program is to 
ensure that health departments and CbOs receive scientifically 
sound and culturally appropriate capacity building assistance 
through the following: 
 technology transfer—translating scientific research into 





barriers to early 
diagnosis of hIv.
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 technical assistance—providing expert programmatic, scientific, 
and technical consultation and support to health department and 
CbO staff
 training—building the knowledge, skills, and abilities that 
health department and CbO staff need to deliver effective 
HIV prevention interventions and to effectively sustain the 
organizational infrastructure needed to support HIV prevention 
services
 information dissemination—sharing information through print 
materials, meetings, Web sites, and mass media 
Diffusion of Effective Behavioral Interventions (DEBI) is 
an example of capacity building using technology transfer to 
disseminate science-based behavioral interventions.  DEbI endorses 
the interventions that are identified by CDC’s Prevention Research 
Synthesis Project.
These interventions are
 Community PROMISE (Peers Reaching Out and Modeling 
Intervention Strategies for HIV/AIDS Risk Reduction in 
their Community), a community-level intervention based on 
behavior change theories
 Healthy Relationships, a small-group intervention for people 
living with HIV and AIDS
 Holistic Health Recovery Program, a group-level program to 
reduce harm and promote health for HIV-infected IDUs
 3MV (Many Men, Many Voices), a group-level STD/HIV 
prevention intervention for MSM of color
 Mpowerment, a community-level intervention for young 
MSM
 Partnerships for Health, a provider-delivered 
counseling program for people living with HIV/AIDS
 POL (Popular Opinion Leader), an intervention 
to identify, enlist, and train key opinion leaders to 
encourage safe behaviors in their social networks 
 RAPP (Real AIDS Prevention Project), a program 
to involve the community in reducing HIV risk and unintended 
pregnancy by increasing condom use 
















 Safety Counts, an intervention for active injection drug and 
crack cocaine users, aimed at reducing high-risk drug use and 
sexual behaviors
 SISTA (Sisters Informing Sisters About Topics on AIDS), 
a group intervention for African American women, to help them 
increase condom use 
 Street Smart, a skills-building program to help runaway and 
homeless youth practice safer sexual behaviors and reduce 
substance abuse
 TLC (Together Learning Choices), an intervention for young 
people, 13–29 years old, who are living with HIV
 VOICES/VOCES (Video Opportunities for Innovative 
Condom Education and Safer Sex), a video-based 
intervention to increase condom use among heterosexual African 
American and Hispanic men and women who visit STD clinics 
 
A second group of interventions will follow. Plans call for diffusion of 
more behavioral interventions as well as structural and biomedical 
interventions.
Evaluation
Evaluation activities focus on results by
 managing and measuring program performance
 improving the quality of HIV prevention programs
 promoting accountability
Program Performance Indicators
As specified in the President’s Management Agenda, CDC has 
incorporated program performance indicators into its cooperative 
agreements with HIV prevention providers.  The purpose is to 
improve performance and accountability of programs. beginning in 
2005 all directly funded health departments and CbOs will report 
on measures of HIV prevention planning, service delivery, and 
evaluation activities.  The performance indicators will be used to 
monitor progress in critical areas of HIV prevention.   The specific 









 prevention activities 
o Counseling, testing, and referral services
o Partner counseling and referral services
o Prevention for HIV-infected persons
o Health education and risk-reduction activities
o Prevention of mother-to-child HIV transmission 
 evaluation of reporting compliance 
 capacity building activities
PEMS (Program Evaluation and Monitoring System) 
CDC has developed PEMS to strengthen monitoring and evaluation 
of HIV prevention programs.  PEMS is to be used by health 
departments and CbOs funded through CDC HIV prevention 
cooperative agreements.  PEMS is a secure Internet browser-based 
software program for data entry and reporting.  PEMS software 
was first released in the fall of 2004 to 42 health departments and 
27 CbOs. It allows grantees to collect agency, community planning, 
and program plan data. The next release, scheduled for fall 2005, 
will enable grantees to enter client-level data and report to CDC.  
by the end of 2005, PEMS will be available to over 200 agencies 
nationwide. PEMS will ensure that CDC receives standardized, 
accurate, and thorough program data from health department and 
CbO grantees. The data include
 agency information
 program plan details
 client demographics
 referral outcomes
 HIV test results
 partner elicitation and notification
 client use of services 
 behavioral outcomes
 community planning priority populations and interventions
These data will allow more comprehensive reporting of HIV 
prevention activities, fiscal information, and community planning 
information.  These data will help HIV prevention stakeholders 
examine program fidelity, monitor use of key program services 
and behavioral outcomes, and calculate and report the program 
performance indicators.   
To improve 
the quality of 
hIv prevention 
programs, CdC 





PEMS will help CDC monitor, evaluate, and coordinate HIV 
prevention programs and support the rapid set-up of special studies 
and evaluation projects.
Research
Among its many HIV research activities, CDC is involved in 





Since November 2002, the Food and Drug Administration has 
approved 4 rapid HIV tests. These tests offer many advantages 
over conventional HIV blood tests. Sample collection is easier (for 
example, from a finger prick or oral fluid), and they 
are easy to use outside of traditional laboratories so 
they are suitable for doctors’ offices and community 
and outreach settings. Perhaps the biggest benefit 
of rapid tests is their ability to give results in 30 
minutes or less. because test results are available 
quickly, rapid HIV tests dramatically increase 
the number of people who get tested and find out 
their results that day. This represents a significant 
public health achievement because those who know 
they are infected with HIV can get treatment. 
Evidence also shows that persons who know they are infected adopt 
changes that dramatically reduce their risk of transmitting the virus 
to others.
Rapid HIV tests also help further reduce the number of infected 
infants born to HIV-infected mothers. HIV transmission from 
mother to infant can be decreased by almost half if antiretroviral 
treatment is started during labor.
CDC is involved in many areas of rapid HIV testing, such as the 
following:
 Evaluating the accuracy of rapid tests
 Providing training on rapid tests




 Publishing information in the scientific literature
 Maintaining an updated Web site
 Helping other federal agencies introduce rapid HIV testing into 
their projects
 Funding demonstration projects
In 2003, CDC funded 21 health departments and CbOs for 2-year 
demonstration projects for rapid HIV tests. These awards are used 
for incorporating rapid testing into routine medical care, partner 
counseling and referral services, short-stay correctional facilities, 
nonclinical settings, and social networks. These projects have shown 
that rapid tests are an important part of HIV prevention efforts.
Microbicides 
CDC is actively involved in research to identify and test potential 
HIV microbicides. Microbicides are gels, creams, or suppositories 
that can kill or neutralize viruses and bacteria. When applied in 
the vagina before sexual intercourse, they can protect against some 
sexually transmitted diseases. A safe, effective, and affordable 
microbicide against HIV could help to prevent many new infections.  
Thailand
CDC collaborated with the Thailand Ministry of Health and the 
Population Council to conduct Phases I and II (safety and efficacy) 
clinical trials of Carraguard, a candidate vaginal gel microbicide, 
in HIV-negative women and heterosexual couples.  Testing of other 
compounds will begin in 2005.  
Botswana
CDC is collaborating with the botswana Ministry of Health to 
develop a site for Phases I, II, and III (safety and efficacy) testing 
of microbicide candidates.  Plans are under way to begin Phase I 
studies in 2006.  
United States
CDC is conducting preclinical (animals and laboratory) and Phases 
I and II clinical trials of potential new HIV microbicides. In its own 
laboratories, CDC is also examining the toxicity and efficacy of some 
microbicides against HIV. 
In November 













CDC is conducting studies to test an antiretroviral agent, tenofovir 
disoproxil fumarate. Tenofovir will be tested for safety, tolerance, 
and effectiveness when used by people at risk before exposure to 
HIV.  Clinical trials began in 2005. Finding a drug that effectively 
prevents HIV without increasing drug resistance could significantly 
affect HIV prevention strategies.
Botswana
CDC is collaborating with the botswana Ministry of Health to 
conduct safety and efficacy trials of tenofovir among heterosexual 
persons at risk for HIV infection.
Thailand
CDC is collaborating with the Thailand Ministry of Health to 
conduct safety and efficacy trials of tenofovir among IDUs. 
United States
CDC is conducting clinical trials among MSM to test for the safety of 
tenofovir.
Vaccines 
The intervention most anticipated by everyone working to stop the 
HIV/AIDS epidemic is a vaccine to prevent infection. CDC is no 
stranger to vaccine development (considering its experience with 
other vaccines such as measles, hepatitis b, polio, and smallpox), but 
developing an HIV vaccine presents unique challenges. For example, 
it is critical that no one (whether involved in the studies or not) 
abandon safer sexual and drug-related behaviors proven to prevent 
HIV infection. Overall, vaccine development must not endanger 
progress already made in HIV prevention.
Until a vaccine is available, and even afterwards, we must continue 
to reinforce the already proven methods of HIV prevention.
CDC’s HIV vaccine research focuses on conducting and evaluating 
HIV vaccine trials in the United States and elsewhere.  CDC played 
an important role in the world’s first 2 efficacy trials of HIV vaccine 
candidates.  Although the results indicated that the vaccines 
were not effective in reducing the risk for HIV infection, the trials 
CdC is actively 
involved in
research to
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provided critical information that will guide 
future research on HIV vaccines.  Through 
an agreement with the National Institutes 
of Health and through membership in the 
Partnership for AIDS Vaccine Evaluation, 
CDC is currently contributing to the US 
government’s effort to develop a safe and 
effective HIV vaccine. 
United States
CDC collaborated with a US vaccine 
developer, VaxGen, in the world’s first 
efficacy trial of an HIV vaccine (AIDSVAX b/b gp 120). At 6 sites, 
CDC also sponsored extensive substudies on how the vaccine 
affected risk behavior.
Thailand
CDC collaborated with VaxGen, the bangkok Metropolitan 
Administration, and Mahidol University to test the efficacy of a 
vaccine (AIDSVAX b/E gp 120) in bangkok. CDC helped develop 
counseling, educational, and prevention materials. CDC and the 
Thai government also identified persons willing to participate and 
to be followed up to evaluate risk behaviors and infection. CDC also 
worked with the community to build the understanding and support 
necessary for such a trial. CDC, Thai health officials, and VaxGen 
ensured that participants received appropriate risk-reduction 
counseling and were fully informed about how the trial worked, the 
potential risks and benefits, and the importance of maintaining good 
risk-reduction behaviors during the trial. CDC also evaluated the 
clinical care and disease progression of participants who become 
HIV-infected during the trial.
Africa
Along with Emory University and the National Institutes of Health, 
CDC helped develop a prototype vaccine (HIV-1 subtype A/G 
DNA+MVA) for people in West/Central Africa.  CDC is also helping 
with preparations for HIV vaccine clinical trials in West/Central and 
East Africa.  In Cameroon and Kenya, CDC is collaborating with 
Ministries of Health to help develop the capacity to conduct HIV 
vaccine clinical trials.  
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Specific	PopulationsFour
Trends among MSM 
hIv-related 
illness and 
death have had 
a devastating 
effect on msm. 
HIV-related illness and death have had a devastating effect on 
MSM. Despite dramatic decreases in AIDS incidence in this 
population, MSM continue to account for the largest number of 
people for whom AIDS is diagnosed each year. Research suggests 
that some MSM are less concerned now than in the past about 
becoming infected and may be inclined to take more risks. This 
trend is backed up by reported increases in other STDs among MSM 
in several large US cities and elsewhere. 
AIDS
MSM accounted for nearly half (42%) of all estimated AIDS cases in 
men and women (including adolescents) diagnosed in 2003. In that 
year alone, 17,969 AIDS cases in MSM were diagnosed, compared 
with 6,353 cases in men who acquired their infection through 
injection drug use, 5,133 through sex with women, and 1,877 
through having sex with men and injecting drugs. 
HIV
Data from the 25 states with long-standing HIV reporting show 
that estimated new HIV diagnoses in MSM declined from 1994 
through 1999 and then began to rise. The increase since 1999 may 
be the result of more people being tested, or it may represent new 
infections. More data are needed to help explain this increase.
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Note:  Data from 25 states that have required HIV reporting since 1994.
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Data reported in 2003 from 41 areas with confidential HIV reporting 
indicate that MSM still represent the largest proportion of new HIV 
cases among men for which risk is known (46%), compared with 
IDUs (11%), men who have sex with women (9%), and MSM who 
inject drugs (3%).
Data from the 2004 National HIV behavioral Surveillance (NHbS) 
system among young MSM surveyed in 5 US cities show that
 prevalence (number living with HIV at a given point in time) and 
incidence (number of new infections over a period of time) of HIV 
are high
 many HIV-infected MSM, especially younger and black MSM, are 
unaware of their infection 
 among MSM with unrecognized infection
o nearly half probably became infected during the past year
o many had not recently been tested because they feared 
positive test results
These findings suggest that the HIV epidemic among MSM is 
continuing well into the third decade and underscore the need to 




Examples	of	CDC Programs and Research for MSM 
Programs for MSM face the challenge of cultural barriers, including 
stigma, especially in communities where black, Hispanic, and other 
men of color live. 
Interventions found to be effective for MSM include 
 small-group lectures on HIV transmission
 training on negotiating condom use and communicating about 
safer sex
 training popular MSM opinion leaders to promote safer sex 
One of CDC’s HIV Prevention Strategic Plan objectives for 
this population is to increase among MSM the proportion who 
consistently engage in behaviors that reduce risk for HIV acquisition 
or transmission.  
CDC activities that address these objectives include 
 Strategies to Address Sexually Transmitted Diseases and 
HIV Transmission among MSM.  In July 2005, CDC held a 
meeting to consult with leaders of gay men’s organizations.  The 
key questions addressed related to how gay organizations and 
CDC could increase awareness of and actions in response to 
increasing rates of syphilis and HIV transmission.
 Joint Internal CDC Workgroup. This group developed a Nine-
Point MSM Plan, which focuses on prevention strategies for 
reaching MSM.
 Behavioral Surveillance. National HIV behavioral 
Surveillance (NHbS) assesses HIV risk behaviors and trends in 
behaviors among MSM in 25 metropolitan areas. 
Programs
CDC provides 40 awards to directly funded CbOs that focus 
primarily on MSM and provides indirect funding through state, 
territorial, and local health departments to organizations serving 
MSM. Of these 40 awards, 68% focus on blacks; 23%, Hispanics; 2%, 
Asians and Pacific Islanders; and 7%, whites. In terms of age groups, 
28% focus on adults; 65%, youth; 3%, elderly people; and 4% are not 
reported.  


















This 4-year study will examine psychological, social, cultural, and 
environmental factors associated with HIV risk behavior among 
black and Hispanic MSM in 3 US cities. The results should shed 
light on how these factors differ between men who become 
infected with HIV and those who remain free of infection. 
Development of prevention messages for MSM
Two research activities have focused on the design of 
prevention messages for MSM.  The first studies assessed 
attitudes toward potential HIV risk-reduction practices, 
knowledge of scientific developments, and potential 
effectiveness of prevention measures focused on risk 
perceptions and behavioral intentions. The second studies 
evaluate message effectiveness and different methods 
for communicating the relative risk of specific sexual 
practices, appeals to protect oneself compared with 
appeals to protect one’s partner, and variations in the 
directness of visual materials and language. 
Project Mix
Project Mix tests a behavioral intervention to reduce 
sexual risk associated with substance use among MSM 
who use alcohol and other noninjection drugs. The 
activities and discussions aim to help the men reduce 
sexual risk behavior and substance use. Participant groups are 
diverse in terms of HIV status, race and ethnicity, sexual orientation 
identification, socioeconomic status, substance use of choice, and 
pattern of substance use. The intervention is being tested in 4 US 
cities.
Rapid HIV Testing at Minority Gay Pride Events
In 2004, CDC and collaborating state and local health departments 
assessed the feasibility of rapid HIV testing at 5 minority gay 
pride events in 4 US cities. Rapid HIV testing at these events was 
determined to be feasible, accepted by clients and staff, and effective 
at identifying persons with previously undiagnosed HIV infection. 
During the summer and fall of 2005, CDC will provide funds to set 
up rapid testing programs at approximately 4 minority gay pride or 









use has directly 
or indirectly 
accounted 
for more than 
one-third (36%) 
of aIds cases 
in the United 
states. 
Drug injection was identified as a risk factor for HIV/AIDS early in 
the epidemic. HIV is transmitted among IDUs who share injection 
drug equipment or have unprotected sex with an infected partner. 
AIDS
Since the beginning of the epidemic, injection drug use has directly 
or indirectly accounted for more than one third (38%) of estimated 
AIDS cases diagnosed in the United States. This association appears 
to be continuing. Of all new cases of AIDS diagnosed in 2003, nearly 
one quarter (22%) were in IDUs. 
Racial and ethnic minority populations are most heavily affected. 
In 2003, injection drug use alone accounted for 25% of all AIDS 
cases diagnosed in black men and women and 24% of all AIDS cases 
diagnosed in Hispanic men and women, compared with only 16% in 
white men and women. 
Among women, injection drug use accounts for a larger proportion of 
AIDS cases than it does among men. Since the epidemic began, 58% 
of all AIDS cases in women have been attributed to injection drug 
use or sex with partners who inject drugs, compared with 34% in 
men. 









1994 1995 1996 1997 1998 1999 2000 2001 2002 2003




The good news is that new HIV diagnoses seem to be declining 
overall among IDUs, with a 53% decrease in estimated new HIV 
diagnoses from 1994 through 2003 in the 25 states with long-
standing HIV reporting.
In 2003, data reported from 41 areas with confidential HIV infection 
reporting showed that among IDUs, blacks accounted for 40% of HIV 







Examples	of	CDC Programs and Research for IDUs
Preventing the spread of HIV through injection drug use requires 
several approaches, including programs to prevent initiation of drug 
use, substance abuse treatment programs, education about HIV 
prevention, and access to sterile needles and syringes for those who 
are unwilling or unable to stop injecting.
Interventions found to be effective for IDUs include 
 skills building for heterosexual women receiving methadone 
treatment
 problem-solving therapy models for incarcerated male adolescent 
IDUs
 training to reduce sexual and drug-related HIV risk behaviors for 
IDUs receiving treatment for substance abuse
One of CDC’s HIV Prevention Strategic Plan objectives for this 
population is to increase among IDUs the proportion who abstain 
from drug use or, for those who do not abstain, increase the 
proportion who use a clean, sterile syringe for each injection to 
reduce risk for HIV acquisition or transmission.
CDC activities that address these objectives include
 Behavioral Surveillance. National HIV behavioral 
Surveillance (NHbS) assesses HIV risk behaviors and trends in 
behaviors among IDUs in 25 metropolitan areas. 
 REP (Replicating Effective Programs). These “prevention in 
a box” projects take interventions proven effective with specific 
populations, including IDUs, and package them into kits for use 
by local HIV prevention agencies. Examples of interventions 
that have proven effective in reducing HIV risk behaviors among 
IDUs include Holistic Health Recovery, Street Smart, and Safety 
Counts.
Programs
CDC provides 4 awards to directly funded CbOs that focus primarily 
on IDUs. Of these 4 awards, 25% focus on blacks; 25%, Hispanics; 
25%, whites; and 25%, American Indians and Alaska Natives. In 
terms of age groups, 100% focus on adults. 
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INSPIRE (Interventions for HIV-Seropositive IDUS—Research and 
Evaluation) 
CDC and the Health Resources and Services Administration jointly 
funded INSPIRE in late 1999 as a 5-year study to link prevention 
and treatment in each of 4 cities (baltimore, Miami, New York, and 
San Francisco). The intervention consists of 10 sessions that focus 
on building cognitive-behavioral skills and encouraging participants 
to mentor their peers. The results from this study are pending. A 
description of the study design, methods, and baseline data was 
published in the Journal of Acquired Immune Deficiency Syndromes 
in 2004. 
DUIT (Drug Users Intervention Trial) 
CDC supports and collaborates on a behavioral intervention trial 
that has been found effective for lowering the risk for HIV and 
hepatitis C infections in IDUs in baltimore, Chicago, Los Angeles, 





Historically, the HIV/AIDS epidemic has affected more men than 
women, but women are being increasingly affected. Since 1985 the 
proportion of estimated AIDS cases diagnosed among women has 
more than tripled, from 8% in 1985 to 27% in 2003. 
AIDS
The epidemic has increased most dramatically among women of 
color. Although black and Hispanic women together represent 
about one fourth of all US women, they account for more than 
three fourths of estimated AIDS cases diagnosed to date among US 
women. In 2003, black and Hispanic women represented an even 
greater proportion (83%) of diagnosed cases in women.
Despite continuing decreases in HIV/AIDS-related deaths in men 
and women, HIV/AIDS remains the fifth leading cause of death in 
the United States for men and women aged 35–44 years and one of 
the top 10 leading causes of death for men and women aged 20–54. 
For blacks in these age groups, HIV/AIDS ranks even higher as a 
cause of death.
HIV
Although each year more men than women become infected with 
HIV, this gap is slowly closing. Data from the 25 states with long-
standing HIV reporting show that new HIV diagnoses in men 
declined 27% from 1994 through 2003.  
Transmission routes differ by gender. Data from 2003 show that
 among men, HIV transmission is estimated to occur 63% through 
sexual contact with men, 14% through injection drug use, and 
17% through sexual contact with women. 
 among women, HIV transmission is estimated to occur 79% 
through sexual contact with men (many of whom are IDUs or also 
have sexual contact with men) and 19% through injection drug 
use.
 Since 1985 
the proportion 
of AIDS cases 
diagnosed among 
women has more 
than tripled, from 
8% in 1985 to 
27% in 2003. 
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Examples	of	CDC Programs and Research for 
Heterosexual	Adults	
Research has shown that women, as well as men, benefit from 
HIV prevention programs. Women benefit from programs aimed at 
increasing their awareness of their own risk, assertiveness in sexual 
situations, and coping skills.
In its funding of prevention programs for women, CDC emphasizes 
 prevention and treatment services for young women and women 
of color 
 better integrated prevention and treatment services for all 
women 
 recognition of the intersection of drug use and sexual HIV 
transmission, especially among women who trade sex for drugs or 
money 
 research on effective female-controlled prevention methods for 
women who are unwilling or unable to negotiate condom use with 
a male partner
 programs with a proven record of effectiveness for changing risky 
behaviors and sustaining those changes over time
Interventions found to be effective include 
 teaching young heterosexual black women about assertiveness, 
negotiation, and condom use
 teaching male and female low-income, urban patients at high 
risk about expectations of outcome, skills, and the belief that 
one’s words and actions will be effective at preventing HIV 
transmission
 showing videos on assertiveness, negotiation, and planning skills 
to promote abstinence and safer behaviors among single, inner-
city pregnant women 
One of CDC’s HIV Prevention Strategic Plan objectives for this 
population is to increase among at-risk sexually active women and 
at-risk heterosexual men the proportions who consistently engage in 
behaviors that reduce risk for HIV acquisition or transmission.  



















CDC activities and strategies that address these objectives include 
 The Revised Recommendations for HIV Screening of 
Pregnant Women
 Behavioral Surveillance. National HIV behavioral 
Surveillance (NHbS) will assess HIV risk behaviors and trends 
in behaviors among high-risk heterosexuals in 25 metropolitan 
areas. Currently, NHbS sites are conducting pilot studies to 
determine the best definition of high-risk heterosexual and places 
to recruit this population for the behavioral surveys.
 
Programs
CDC provides 22 awards to directly funded CbOs that focus 
primarily on women. Of these 22 awards, 54% focus on blacks; 41%, 
Hispanics; and 4%, whites. In terms of age groups, 45% focus on 
adults; 45%, youth; and 10% are not reported.  
Using Social Network Strategies for Reaching Persons at High Risk 
for HIV Infection in Communities of Color  
In October 2003, funding was awarded to 9 CbOs in 7 cities to 
demonstrate the feasibility of using social network strategies to 
reach persons at high risk for HIV infection and provide them HIV 
counseling, testing, and referral services. As of September 2004, the 
133 enlisted recruiters had referred 814 persons from their social, 
sexual, or drug-using networks to get tested for HIV.  For the 46 
(6%) who received positive test results, this was the first time they 
learned that they were HIV-infected.
Research
Safe City Project
The Safe City Project, which began in October 2001, was designed 
to develop and evaluate a video-based prevention intervention for 
patients in STD clinics. The primary goals are to assess whether 
showing a brief 23-minute educational video to male and female 
patients in the waiting room can reduce risky sexual behaviors 
and new STDs for these patients.  After 3 months, researchers will 
compare levels of high-risk sexual behavior between the 900 patients 
who saw the video and another 900 who did not. After 1 year, they 





People of color are disproportionately affected by the HIV/AIDS 
epidemic. In the early 1980s, most AIDS cases occurred in whites. 
However, cases in blacks increased steadily, and by 1996 more cases 
occurred in blacks than in any other racial or ethnic population. 
AIDS cases have also increased in Hispanics, Asians, Pacific 
Islanders, American Indians, and Alaska Natives.  
AIDS 
Although blacks represent a small proportion (13%) of the US 
population, they accounted for a large proportion of the estimated 
cumulative AIDS cases (40%) and AIDS deaths (37%) through 2003. 
Likewise, Hispanics represent about 12% of the US population, but 
they accounted for an estimated 19% of AIDS cases and 18% of AIDS 
deaths through 2003. 
In terms of risk groups for black men for whom AIDS was diagnosed 
in 2003, MSM represent 46%; IDUs, 25%; and heterosexuals, 23%. 
Of risk groups for Hispanic men with AIDS, MSM represent 53%; 
IDUs, 23%; and heterosexuals, 17%. 
Among black women for whom AIDS was diagnosed in 2003, 
injection drug use accounted for an estimated 25% of all cases and 
heterosexual contact for 72%. Among Hispanic women with AIDS, 
heterosexual contact accounted for an estimated 71% of cases and 
injection drug use for 27%. 
HIV
The disparity between black and white people continues. Data from 
the 25 states with long-standing HIV reporting from 1994 through 
2003 indicate that an estimated 55% of people with a new diagnosis 
of HIV were black (and not Hispanic), compared with 35% who were 
white (and not Hispanic). New HIV diagnoses from 1994 through 
2003 declined more sharply among whites (31%) than among blacks 
(24%).  Of the roughly 1 million people estimated to be living with 






















Note:  Data from 25 states that have required HIV reporting since 1994.















Examples	of	CDC Programs and Research for  
People	of	Color
CDC is committed to working with communities of color to ensure 
that those who have been disproportionately affected by HIV/AIDS 
have access to early testing, treatment, and prevention services and 
programs that work.
Interventions found to be effective for people of color include 
 using culturally appropriate videos to teach small groups of 
sexually active black and Hispanic men and women about 
condom use, negotiation skills, and safer sex
 teaching health care providers how to work with young black and 
Hispanic MSM and heterosexuals in prevention activities
 providing risk-reduction activities; access to HIV counseling, 
testing, and referral services; and prevention information to black 
youth
 training black youth as peer educators in their communities
 offering HIV counseling and testing services and outreach 
activities to black churches and offering outreach, discharge 
planning, community case management, and education services 
to correctional institutions
The CDC HIV Prevention Strategic Plan’s overarching national 
goal focuses on eliminating racial and ethnic disparities in new HIV 
infections. 
CDC activities that address this goal include
 Supplemental Funding for Community-based Strategies 
to Increase HIV Testing of Persons at High Risk in 
Communities of Color.  These funds support a social network 
model to increase HIV counseling and testing among high-risk 
minority communities. 
 Research Fellowship on HIV Prevention in Communities 
of Color. This program supports the training of scientists 
researching sociocultural, structural, psychological, and 
behavioral factors in minority health and HIV.
 MARI (Minority HIV/AIDS Research Initiative). This 
capacity-building initiative funds investigators working on  
HIV/AIDS research gaps in black and Hispanic communities.















CDC provides more than $300 million to help communities build and 
sustain sound, innovative HIV prevention programs. In addition, the 
Minority AIDS Initiative provides funding to state and local health 
departments for HIV prevention resources for minority populations 
at high risk. CDC provides 179 awards to directly funded CbOs that 
focus primarily on people of color. Of these 179 awards, 59% focus 
on blacks; 25%, Hispanics; 13%, Asians and Pacific Islanders; and 
1% American Indians and Alaska Natives. In terms of age 
groups, 69% focus on adults; 25%, youth; and 6%, elderly 
people.
Using Social Network Strategies for Reaching Persons at 
High Risk for HIV Infection in Communities of Color  
In October 2003, funding was awarded to 9 CbOs in 7 
cities to demonstrate the feasibility of using social network 
strategies to reach persons at high risk for HIV infection 
and provide them HIV counseling, testing, and referral 
services. As of September 2004, the 133 enlisted recruiters 
had referred 814 persons from their social, sexual, or drug-
using networks to get tested for HIV.  For the 46 (6%) who 
had positive HIV test results, this was the first time they 
learned that they were HIV-infected. 
Research 
Project START  
Conducted at 4 sites from 1998 through 2003, this HIV 
and STD prevention project is for young men being released from 
prison.  At 24 weeks after release, men who received an enhanced 
intervention (before and after release) were significantly less likely 
to report having had unprotected sex during their most recent 
sexual encounter (59%) than were men who received a 1-session 
intervention (69%) before release.
Brothers y Hermanos  
This 4-year study will examine psychological, social, cultural, and 
environmental factors associated with HIV risk behavior among 
black and Hispanic MSM in 3 US cities. The results should shed 
light on how these factors differ between men who become infected 





The HIV/AIDS epidemic has taken a heavy toll on young people 
in the United States. because it is presumed that young people 
with HIV were infected fairly recently, scientists believe that HIV 
infections among youth may indicate trends in the overall HIV/AIDS 
epidemic. Trends in STDs other than HIV among young persons 
serve as indicators of risk behaviors for HIV.  
AIDS
From the beginning of the epidemic through 2003, an estimated 
9,789 young people (aged 15–24 years) with AIDS have died. 
Fortunately, since the late 1980s (from 1989 through 2003), deaths 
from AIDS have declined 71% for people in this age group.  However, 
the challenges of addressing disparities in care, preventing 
secondary transmission of HIV, and meeting the social and medical 
needs of persons living with HIV or AIDS are especially critical for 
youth, considering their long-term needs. 
HIV
Data from the 25 states with long-standing HIV reporting show 
that among people aged 25–34 years, the estimated number of new 
diagnoses from 1994 through 2003 declined by a remarkable 49%. 
However, in youth aged 13–24, new HIV diagnoses remained stable 
during this time period.
The hIv/aIds 
epidemic has 
taken a heavy 
toll on young 
people in the 
United states. 












Note:  Data from 25 states that have required HIV reporting since 1994.
HIV Diagnoses, by Age










Young women and young black men and women are being 
increasingly affected by HIV. In 2003, data reported from 41 areas 
with confidential HIV reporting showed that young women account 
for nearly half (40%) of HIV infections in those aged 13–24 years. 
black youth have been most heavily affected, accounting for 55% of 
all HIV infections reported among those aged 13–24 in areas with 
confidential HIV reporting. 
Young MSM, especially those of color, are also at high risk for HIV 
infection. The CDC Young Men’s Survey showed that from 1994 
through 1998, 14% of black MSM and 7% of Hispanic MSM aged 




Examples	of	CDC Programs and Research for Youth












reduce risk for 
hIv acquisition 
or transmission.
Prevention research has identified many interventions that help 
young people adopt healthier behaviors.  Parents have been shown 
to be powerful resources.  CDC’s primary message for youth is 
abstinence.
Interventions CDC has found effective with youth include 
 holding small-group discussions among young MSM about 
reducing unsafe sexual behaviors, training others to conduct 
informal outreach, and conducting a publicity campaign
 teaching runaway youth safer behaviors through role-playing 
and problem-solving exercises to help them identify triggers and 
decrease harmful behavior
 teaching students to postpone sex and reduce unsafe sexual and 
drug-using behaviors
One of CDC’s HIV Prevention Strategic Plan objectives for this 
population is to increase among adolescents the proportion who 
consistently engage in behaviors that reduce risk for HIV acquisition 
or transmission.
CDC activities that address this goal include
 HIV Prevention Projects for Community-based 
Organizations Targeting Young Men of Color Who Have 
Sex with Men. These programs create, put into place, and 
sustain services to help prevent HIV in young MSM of color, their 
sex partners, and transgendered youth. 
 Pregnancy in Perinatally Infected Youth. This study looks at 
teenagers who had acquired HIV from their mothers and are now 
pregnant and having their own children.
 REP (Replicating Effective Programs). This “prevention in 
a box” project takes interventions proven effective with specific 
populations and packages them into kits for use by local HIV 
prevention agencies. Of 10 interventions, 3 serve youth only and 
2 others include youth in their populations served.
 School-based HIV Prevention. These programs support 
48 state education agencies, 18 large city education agencies, 
7 territorial agencies, and 37 national nongovernment 
organizations to help set up school health programs that provide 
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young people with skills and information to avoid or reduce 
behaviors that put them at risk for HIV infection.  In 2003, 88% 
of all high school students reported receiving HIV prevention 
education.
Programs
CDC provides 36 awards to directly funded CbOS that focus 
primarily on youth and provides indirect funding through state, 
territorial, and local health departments to organizations serving 
youth. Of these 36 awards, 75% focus on blacks; 19%, Hispanics; 3%, 
Asians and Pacific Islanders; and 3%, whites. 
Parents Matter!  
This community-based intervention promotes effective parenting 
and parent-child communication to reduce sexual risk. Although 
parents are in a unique position to provide early and continuous HIV 
prevention messages, many lack the information, skills, comfort, or 
confidence to do so.  
Partnership for Adolescent Wellness Study (PAWS) 
PAWS is a formative research study of black youth (aged 12–17 
years) whose mothers use crack cocaine.  Conducted in 2 cities in 
North Carolina, the study explores what influences HIV-related risk 
behaviors of these young people. 
Research
CITY (Community Intervention Trials for Youth) 
CITY evaluated approaches for encouraging young men who engage 
in HIV-risk behaviors, especially racial and ethnic minorities aged 
15–25, to change these behaviors.  
YMS (Young Men’s Survey) 
This study, conducted in 2 phases (1994–1998 and 1998–2000), 
measured HIV infection (and hepatitis and syphilis) and related risk 
behaviors of young MSM.  
YWS (Young Women’s Survey) 
This survey, conducted in 1999, examined sexual behaviors and HIV 






Trends among Pregnant Women and their Infants
HIV transmission from mother to child (also called perinatal 
transmission) can occur during pregnancy, labor, delivery, or breast-
feeding. Mother-to-child HIV transmission accounts for over 90% of 
all AIDS cases in US children. 
During the early to mid 1990s, 6,000 to 7,000 HIV-infected women 
gave birth each year. An estimated 1 in 4 of these newborns acquired 
the mother’s HIV infection. Had this transmission rate continued, 
an estimated 1,750 HIV-infected infants would have been born in 
the United States each year, and lifetime medical costs for these 
infants may have reached $282 million. Fortunately, this trend was 
successfully interrupted. With current estimates being 280 to 370 
perinatal infections each year and costs per individual $185,000, 
lifetime costs are closer to $60 million.  
This decline in the number of HIV-infected infants occurred after 
the 1994 and 1995 US Public Health Service recommendations for 
preventing mother-to-child HIV transmission. 
The recommendations include 
 routinely offering counseling and voluntary HIV testing to 
pregnant women 
 offering zidovudine (also called ZDV or AZT) treatment to HIV-
infected women during pregnancy and delivery 
 treating the infant with zidovudine after birth
Most pregnant women voluntarily accept HIV testing if it is offered 
by their health care provider. Testing rates are higher in areas 
with voluntary opt-out policies (in which testing is routine unless a 
woman chooses to not be tested) and mandatory testing of newborns.
between 1992 and 2003, estimated cases of perinatally acquired 












However, children of color—especially black children—continue 
to be disproportionately affected by AIDS. Although only 16% 
of US children are black, 67% of US children with a diagnosis of 
perinatally acquired AIDS in 2003 were black. 
HIV exposure risks for mothers of children with AIDS have changed 
over time. In the early 1980s, most women were exposed to HIV 
through injection drug use and a smaller proportion through sex 
with men. However, during the 1990s, these proportions reversed; 
the mother’s exposure through sex with men now plays a larger role 












Examples	of	CDC Programs and Research for  
Pregnant Women and their Infants 
Efforts to prevent mother-to-child HIV transmission must focus on 
preventing new HIV infections in women; providing timely prenatal 
care and HIV testing during pregnancy (including rapid HIV testing 
during labor); and making sure all HIV-infected pregnant women 
receive care, prevention case management, and treatment.
One of CDC’s HIV Prevention Strategic Plan objectives is to increase 
the proportion of pregnant women who are tested for HIV and, if 
infected, choose to take medication to interrupt mother-to-child 
transmission of HIV.  One of the goals of CDC’s recently launched 
initiative, Advancing HIV Prevention, is to further decrease mother-
to-child transmission of HIV.
Program
Perinatal Elimination Efforts
Since 1999, Congress has provided $10 million a year to reduce 
mother-to-child transmission of HIV in the United States. CDC 
distributes these funds to 
 10 state and city jurisdictions for enhanced perinatal surveillance
 16 state prevention programs serving pregnant women at high 
risk for HIV
 5 national health care provider organizations to develop training 




EPS (Enhanced Perinatal Surveillance)
EPS is one of CDC’s activities to further reduce mother-to-child 
transmission of HIV in areas with high levels of HIV.  EPS is an 
extension of routine surveillance activities. Its goals are to 
 monitor 
o adherence to US Public Health Service recommendations for 
HIV counseling and voluntary testing of pregnant women
o use of medication regimens recommended by the US Public 
Health Service to prevent mother-to-child transmission of 
HIV 
o effect of the recommendations on trends of HIV disease in 
children
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 establish a surveillance system that collects data to help states 
respond to certain requirements of the Ryan White CARE Act
 assist in timely evaluation of efforts to prevent mother-to-child 
transmission of HIV 
EPS data from 24 sites from 1999 through 2001 show that 1 in 8 
(12%) HIV-infected women did not receive prenatal care, and 1 in 10 
(10%) did not get tested for HIV before giving birth.   
MIRIAD (Mother Infant Rapid Intervention at Delivery)
The MIRIAD project has shown that rapid HIV testing during labor 
for women whose HIV status is unknown is acceptable, 
effective, and feasible. CDC has a national plan for rapid HIV 
testing of pregnant women. CDC published a model protocol 
for hospitals, updates the protocol as new rapid HIV tests 
become licensed, and funds regional trainings for several US 
hospitals.  
LEGACY (Longitudinal Epidemiologic Study to Gain Insight 
into HIV and AIDS in Children and Youth)  
LEGACY is a new study of HIV-infected children and 
adolescents, from birth through 24 years, who are receiving 
care from a pediatrician or specialist in adolescent medicine. 
The study is being conducted at approximately 20 sites 
throughout the United States.  The study will monitor trends 
in
 illness and death in HIV-infected children and adolescents, 
including how their disease is progressing, how well their 
immune system is working, any long-term complications from the 
disease or its treatment, and how long they are living 
 use of antiretroviral drugs and any side effects or viral resistance 
from long-term treatment with these drugs
 factors that may be related to the risk for secondary transmission 





Rates of HIV and AIDS are high among correctional facility inmates; 
similarly, rates of incarceration are high among HIV-infected 
people. Many inmates (12% according to a 2002 Supplement to 
HIV/AIDS Surveillance study) receive their diagnosis of HIV while 
incarcerated. 
AIDS
The rate of confirmed AIDS cases for state and federal inmates 
(48/10,000) is more than 3 times the rate for the general US 
population (14/10,000).  In 2002, the prevalence of AIDS was 0.5% 
for inmates in state prisons and 0.4% for inmates in federal prisons. 
About 20% of inmates known to be HIV-infected also had a diagnosis 
of AIDS.
Fortunately, effective therapies have led to marked increases in the 
survival of inmates with AIDS. The number of AIDS-related deaths 
of inmates has been decreasing dramatically since it peaked in 1995; 
by 2002, the number of AIDS-related deaths in state prisons had 
declined 72%. In 2002, the reported number of AIDS-related deaths 
was 215 for state inmates and 17 for federal inmates. AIDS-related 
deaths accounted for 5% of all deaths in federal prisons. 
People Living with AIDS, Inmates and General Population 
 
Note: The shaded area covers the period prior to the 1993 expansion of the classification system for HIV 
infection and the case definition for AIDS. This expansion improved estimates of the number and the 
characteristics of persons with HIV disease but complicated interpretation of AIDS trends. The increase in 
reported AIDS cases in 1993 was largely the consequence of the added surveillance criteria. 
 




At the end of 2002, 2.0% of state prison inmates and 1.1% of federal 
prison inmates were known to be HIV-infected.  The total number of 
inmates known to be HIV-infected was 23,864. In 2002, the highest 
rates of HIV infection for inmates occurred in the Northeast, where 
4.6% of the prison population was HIV-infected, followed by 2.2% 
in the South, 1.0% in the Midwest, and 0.7% in the West.  In state 
prisons, a higher percentage of female (3.0%) than male (1.9%) 
inmates were HIV-infected. 
Rates of hIv 













Examples	of	CDC Programs and Research for 
Correctional	Facility	Inmates
Trends in HIV and AIDS in correctional facilities affect not 
only inmates but the general public because many inmates 
(approximately 7.5 million per year) are released back into the 
community. However, most correctional facilities have inadequate 
or no discharge planning (plans for linking released inmates with 
community-based health care, substance abuse treatment, and other 
services). CDC uses a community approach to improve the health of 
inmates by collaborating with correctional facilities, public health 
agencies, and community health care and social service providers. 
because approximately 80% of prisoners have a history of substance 
use, some HIV prevention programs for inmates focus on IDUs. 
Program
CDC/HRSA Corrections Demonstration Project
CDC and the Health Resources and Services Administration (HRSA) 
jointly funded 7 states for this project.  The project’s purpose was 
to develop, set up, and evaluate models for innovative programs 
to provide continuity of care (follow-up care after release). Using 
outreach, HIV education, and HIV/AIDS counseling and testing, 
the project served inmates, especially racial and ethnic minorities, 
who were HIV-infected or at risk for HIV infection. The project 
encouraged collaborations between correctional facilities, public 
health agencies, CbOs, and health care providers.  Evaluations 
will focus on whether health outcomes were improved by linking 
discharged inmates to services and keeping them in services. 
Routine Rapid HIV Testing of Inmates in Short-stay Correctional 
Facilities
State health departments in Florida, Louisiana, New York, 
and Wisconsin have been funded to offer HIV rapid testing and 
prevention counseling as a standalone procedure to male and female 
inmates.  All inmates are confidentially notified of their test results 
at the time of rapid testing. Inmates with preliminary positive HIV 
rapid test results are offered confirmatory HIV testing.  Inmates 
with a positive confirmatory result are referred to appropriate care, 





March 2005, a total of 16,676 rapid tests have been conducted.  Of 
these, 256 (1.5%) were reactive. Of the 236 persons who consented to 
confirmatory HIV testing, 200 had confirmed positive test results; of 
these, 121 (61%) were newly identified infections.  Routinely offering 
voluntary rapid HIV testing with other STD screening as 
a component of the medical evaluation may increase use.  
Provision of consistent, high-quality counseling and testing 
services could potentially build trust between inmates 
and staff and improve program acceptance and success. A 
comprehensive guidance document on implementing HIV 
rapid testing in jails will be developed after project activities 
have been completed.
Research
CDC Corrections Discharge Planning Study
CDC funded this study of discharge planning and continuity of care 
for HIV-infected releasees in 10 states. Questionnaires and follow-
up phone interviews identified state-of-the-art practices and factors 
that help or hinder discharge planning and continuity of care. The 
findings indicated that 
 discharge planning should be holistic and tailored to the 
individual
 continuity of medical care is most likely when releasees receive
o medication at the time of release
o a printed summary of their prison medical records 
o a medical appointment in the community
o help applying for medical and cash benefits (eg, Medicaid, 
AIDS Drug Assistance Program)
Project START
Conducted at 4 sites from 1998 through 2003, this HIV/STD 
prevention project is for young men being released from prison.  It 
compared sexual risk after a 1-session intervention (before release) 
to that after an enhanced intervention (before and after release).  At 
24 weeks after release, men who received the enhanced intervention 
were significantly less likely to report having had unprotected sex 
during their most recent sexual encounter (59%) than were men who 





HIV and AIDS pose one of the greatest challenges to global public 
health. Worldwide in 2004, more than 3 million people died from 
AIDS. During that same year, an estimated 5 million people 
acquired HIV, bringing the number of people living with HIV to 39 
million. Especially vulnerable are disadvantaged, marginalized, and 
unempowered populations such as commercial sex workers, IDUs, 
MSM, women and girls, and people living in poverty. Many people 
do not know that they carry the virus. Millions more know nothing 
or too little about HIV to protect themselves against it. Even those 
who do know about HIV prevention may not have the power to act 
on it, especially women and girls, who are often unable to say no to 
unprotected sex or to negotiate safer behaviors.
Sub-Saharan	Africa	
Approximately 25.4 million people are living with HIV/AIDS; an 
estimated 3.1 million were newly infected with HIV in 2004.  
HIV/AIDS is the leading cause of death in sub-Saharan Africa. 
In 2004 alone, AIDS killed 2.3 million African people. Without 
adequate treatment and care, most of those living with HIV will not 
survive the next decade. 
Asia	and	the	Pacific	
Approximately 8.2 million people are living with HIV/AIDS; an 
estimated 1.2 million were newly infected in 2004. New infections 
increased 8% since 2002. The epidemic claimed over 540,000 lives 
in 2004. High HIV infection rates in the region are being discovered 
among IDUs, MSM, and sex workers.
Latin America and the Caribbean 
Approximately 2.1 million people are living with HIV/AIDS; an 
estimated 293,000 were newly infected in 2004. Driving the spread 
of HIV are unequal socioeconomic development and a highly mobile 
population. The region, however, has made admirable progress in 
providing treatment and care.  
hIv and aIds 








Approximately 1.6 million people are living with HIV/AIDS; an 
estimated 70,000 were newly infected in 2004. A larger epidemic 
threatens to develop in high-income countries. Unsafe sex and 
widespread injection drug use are propelling these epidemics, which 
are shifting more toward underprivileged communities.  
Eastern	Europe	and	Central	Asia	
Approximately 1.4 million people are living with HIV/AIDS; an 
estimated 210,000 were newly infected in 2004. Eastern Europe—
especially the Russian Federation—continues to experience the 
fastest growing epidemic in the world.  because of high levels 
of other STDs and injection drug use among young people, the 
epidemic may grow considerably.  
The	Middle	East	and	North	Africa	
Approximately 540,000 people are living with HIV/AIDS; an 
estimated 92,000 were newly infected in 2004. Poor surveillance 
systems in several countries hinder accurate assessment of and 
response to the epidemic.  
Adults and Children Estimated to be Living with HIV, 2004 




Examples	of	CDC Programs and Research for  
People	Worldwide
For many years, CDC has been working with others to fight  
HIV/AIDS around the world. The international goal of CDC’s HIV 
Prevention Strategic Plan is to assist in reducing HIV transmission 
and improving HIV/AIDS care and support in partnership with 
resource-constrained countries.
Program
CDC’s Global AIDS Program (GAP)
CDC’S Divisions of HIV/AIDS Prevention provide support and 
technical assistance for GAP. Under the direction of the US Global 
AIDS Coordinator’s Office, CDC’s Global AIDS Program (GAP) is a 
major partner in the effort to address the Emergency Plan for AIDS 
Relief, announced by President bush in his 2003 State of the Union 
address. The goals of the Plan are to 
 treat 2 million HIV-infected people
 prevent 7 million new HIV infections
 care for 10 million people (people living with HIV and children 
orphaned because of HIV) in 15 of the world’s most affected 
countries 
 
As of 2004, GAP has programs in 25 countries and 4 regional 
programs in Africa, Asia, Latin America, and the Caribbean. GAP 
provides assistance directly through its own staff and through 
partnerships with governments, communities, and other national 
and international groups.
GAP’s mission is to 
 prevent HIV infection
 improve care, support, and treatment for people living with  
HIV/AIDS




goal of CdC’s 
HIV Prevention 
strategic Plan 












GAP’s priority areas include 
 providing support for HIV/AIDS surveillance systems
 enhancing voluntary counseling and testing programs and 
services
 strengthening laboratory capacities and systems 
 providing care, support, and treatment for people living with 
HIV/AIDS
 reducing mother-to-child transmission of HIV 
 training program staff 
CDC Global AIDS Program Countries
Research 
The focus of CDC’s international HIV research is developing and 
testing potential HIV vaccines and microbicides as well as looking 
for new ways to reduce mother-to-child HIV transmission. CDC is 
also involved in providing technical support for programs working 
with drugs for HIV treatment; these programs aim to improve care 
for people with HIV and to prevent HIV transmission from mother to 
child. CDC’s international HIV/AIDS research is mostly conducted 
in GAP field stations with staff assigned to botswana, Kenya, and 
Thailand. In addition, CDC is involved in collaborative research 









Advancing HIV Prevention: New Strategies for a 
Changing Epidemic
Advancing HIV Prevention (AHP) is an initiative to reduce barriers 
to early diagnosis of HIV infection and increase access to quality 
medical care, treatment, and ongoing prevention services for people 
living with HIV. 
This initiative was created in response to several factors.
 Declines in new HIV infections have leveled off.
 Increases in sexually transmitted diseases and risk behaviors 
have led to a possible increase in new HIV infections.
 Not enough people know their HIV status.
 People who know their HIV status can protect themselves and 
their partners.
 A simple, rapid HIV test is available.
 Opportunities for preventing mother-to-child HIV transmission 
are being missed. 
Four strategies are used to advance HIV prevention.
1. Make voluntary HIV testing a routine part of medical care. CDC 
is working with medical associations to ensure that all health 
care providers include HIV testing, when indicated, as part of 
routine medical care. 
2. Use new models for diagnosing HIV infections outside medical 
settings.  The use of rapid HIV tests can increase access to early 
diagnosis and referral for treatment and prevention services. 
3. Prevent new infections by working with HIV-infected persons 
and their partners.  CDC published the Recommendations for 
Incorporating HIV Prevention into the Medical Care of Persons 
with HIV Infection. 
4. Further decrease mother-to-child HIV transmission.  CDC 
promotes routine HIV testing of pregnant women and routine 
screening of any infant whose mother was not tested.
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What	Are	CDC’s	Plans? Five
Although AHP emphasizes voluntary HIV testing, it does not 
endorse mandatory testing.  AHP capitalizes on rapid test 
technologies, interventions that bring persons who are unaware of 
their HIV status to HIV testing, and behavioral interventions that 
provide prevention skills to persons living with HIV.  
Overall, 9 health departments and 16 CbOs have been awarded $23 
million over 2 years to develop models and demonstrate feasibility 
of putting the 4 AHP strategies into practice.  As the first round of 
projects comes to a close, lessons learned are being used to develop 




HIV Rapid Testing to Improve Outcomes for Partner Counseling, 
Testing, and Referral Services (PCTRS).  
For this project, health departments in Colorado, Chicago, Los 
Angeles, Louisiana, San Francisco, and Wisconsin have been 
awarded contracts totaling $2.7 million.  As of June 2004, all 6 
health departments had incorporated HIV rapid testing into their 
PCTRS activities. by March 2005, they had tested 279 partners of 
persons with a diagnosis of HIV and found that 25 (9%) of these 
partners were HIV-infected.  
 
Routinely Recommending HIV Testing as Part of Regular Medical 
Care Services.  
In 4 health department jurisdictions, 12 facilities in urban areas 
with high prevalence of HIV have been funded to evaluate the 
feasibility and sustainability of offering HIV testing to eligible 
clients as a routine part of medical care in clinical settings. The 
facilities, which include emergency departments, outpatient clinics, 
and a dental clinic, are in Wisconsin, Massachusetts, Los Angeles, 
and New York State. All facilities started testing by June 2004. Each 
will test at least 1,500 persons per year and will facilitate access to 
care for at least 80% of those whose test results are positive. As of 
March 2005, 9,578 people had been tested and results were positive 




Routine Rapid HIV Testing of Inmates in Short-Stay Correctional 
Facilities. 
State health departments in Florida, Louisiana, New York, 
and Wisconsin have been funded to offer HIV rapid testing and 
prevention counseling as a standalone procedure to male and female 
inmates.  All inmates are confidentially notified of their test results 
at the time of rapid testing. Inmates with preliminary positive 
HIV rapid test results are offered confirmatory HIV testing and 
result notification.  Inmates with a positive confirmatory result are 
referred to appropriate care, treatment, and prevention services. 
From January 2004 through March 2005, a total of 16,676 rapid 
tests have been conducted.  Of these, 256 (1.5%) were reactive. 
Of the 236 persons who consented to confirmatory HIV testing, 
200 had confirmed positive test results; of these, 121 (61%) were 
newly identified infections.  Routinely offering voluntary rapid HIV 
testing with other STD screening as a component of the medical 
evaluation may increase use.  Provision of consistent, high-quality 
counseling and testing services could potentially build trust between 
inmates and staff and improve program acceptance and success. 
A comprehensive guidance document on implementing HIV rapid 
testing in jails will be developed after project activities have been 
completed. 
AHP Demonstration Projects for CBOs 
Prevention Case Management for Persons Living with HIV/AIDS 
(now called Comprehensive Risk Counseling and Services). 
Funding has been awarded to 9 CbOs to provide prevention case 
management (PCM) to HIV-infected persons who have many and 
complex needs for HIV risk reduction. The CbOs are in Maryland; 
Massachusetts; Michigan; Missouri; California; Pennsylvania; New 
York; and Washington, DC.  As of April 2005, 719 HIV-infected 
persons had been screened. Of the 546 HIV-infected persons who 
were eligible for PCM because of continuing risk behaviors, 402 had 
enrolled in PCM and attended an average of 4 to 7 sessions.  HIV-
infected persons may need a variety of services, such as substance 
abuse counseling, to help them reduce and eventually eliminate 
their high-risk behaviors.  It is important for such services to be 




Rapid HIV Testing in Nonclinical Settings. 
Funding has been awarded to 8 CbOs to provide rapid HIV testing 
in nonclinical settings, such as parks, shelters, and night clubs.  The 
settings are in Los Angeles; San Francisco; Detroit; Washington, DC; 
Kansas City, Missouri; boston; and Chicago. As of March 2005, 180 
(1.5%) of the 12,334 persons tested were HIV-infected. 
Using Social Network Strategies for Reaching Persons at High Risk 
for HIV Infection in Communities of Color. 
Funding has been awarded to 9 CbOs in 7 cities to demonstrate the 
feasibility of using social network strategies to reach persons at high 
risk for HIV infection and provide them HIV counseling, testing, 
and referral services. The CbOs are in Philadelphia (2); Orlando; 
San Francisco (2); New York; boston; Lafayette, Louisiana; and 
Washington, DC. In October 2003, funding was awarded to 9 CbOs 
in 7 cities to demonstrate the feasibility of using social network 
strategies to reach persons at high risk for HIV infection and provide 
them HIV counseling, testing, and referral services. As of September 
2004, the 133 enlisted recruiters had referred 814 persons from 
their social, sexual, or drug-using networks to get tested for HIV.  
For the 46 (6%) who received positive test results, this was the first 
time they learned that they were HIV-infected. Preliminary findings 
indicate that social network strategies are effective for reaching 
people and accepted by a variety of people, regardless of gender, age, 
race and ethnicity, and HIV risk category.
AHP	Demonstration	Projects	for	Primary	Care	Providers
Incorporating HIV Prevention into Medical Care Settings. 
Funding has been awarded at 6 sites to help providers incorporate 
HIV prevention into medical care. The sites are in Chapel Hill; 
Denver; Atlanta; Nashville; brooklyn; and Kansas City, Missouri. 
Of an anticipated 1,200 patients, 1,124 were recruited in 2004. 
All sites completed provider training and have started a patient 
intervention called Positive STEPs (Striving to Engage People). 
Follow-up interviews are in progress and will end by December 
2005. HIV prevention materials developed for the project have been 
well received by participating clinics and may be suitable for future 





HIV Testing in Historically Black Colleges and Universities and 
Alternative Venues and Populations. 
New models for diagnosing HIV infection by providing greater access 
to HIV testing and prevention and care services are being tested in 
sites that serve migrant and seasonal farm workers, communities 
with transgendered persons, communities with Native Americans, 
and historically black colleges and universities.  These people 
are among those less often reached by health promotion efforts.  
Information from this project can be used to reduce the barriers that 
make it difficult for communities to access HIV testing and services.
Antiretroviral Treatment and Access Study II (ARTAS II). 
To improve access to HAART for people who have just received a 
diagnosis of HIV, linkage case management is being explored at 11 
sites:  5 health departments and 6 CbOs.  Whereas the first ARTAS 
study showed linkage case management to be effective, ARTAS II 
will compare rates of linkage to HIV care providers before and after 
instituting linkage case management. Findings will strengthen 
our understanding of how well linkage case management works in 






The HIV Prevention Strategic Plan is CDC’s original approach to 
the challenges of the third decade. Published in 2001, it became a 
blueprint for actions to reduce HIV and AIDS in the United States 
and around the world.  Although it is a CDC plan, its success 
depends on collaboration with many organizations and agencies, 
each of which is essential to achieving the plan’s goals, objectives, 
and strategies.  
Overarching	Goal
Decrease new HIV infections in the United States by half (from 
40,000 to 20,000 new infections per year), focusing particularly on 
eliminating racial and ethnic disparities.
Four national goals have been set to accomplish this in the United 
States. 
 Decrease by at least 50% the number of persons at high risk of 
acquiring or transmitting HIV infection by delivering targeted, 
sustained, and evidence-based HIV prevention interventions. 





o Sexually active women and heterosexual men who are 
at risk for HIV 
 Through voluntary counseling and testing, increase from 
the current estimated 75% to 95% the proportion of HIV-infected 
persons who know they are infected.
 Increase from the current estimated 50% to 80% the proportion of 
HIV-infected persons who are linked to appropriate prevention, 
care, and treatment services.
 Strengthen the capacity nationwide to monitor the epidemic, 
develop and implement effective HIV prevention interventions, 
and evaluate prevention programs. 
International Goal
To assist in reducing HIV transmission and improving HIV/AIDS 
care and support in partnership with resource-constrained countries.
The hIv 
Prevention 








More About HIV Prevention
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adherence to therapy—Taking medications as prescribed. 
AIDS (acquired immunodeficiency syndrome)—A specific 
group of diseases or conditions that indicate severe suppression 
of the immune system related to infection with the human 
immunodeficiency virus (HIV).
AIDS case definition—A standard definition of the physical and 
laboratory findings that make up an AIDS case. In 1993, the 
AIDS case definition was expanded to include a broader range of 
diseases and conditions and the results of immunologic testing, 
such as CD4+ T-cell counts. Consequently, the number of AIDS 
cases in 1993 was transiently elevated by the rapid reporting of 
cases not previously reported using the old definition. 
antibody—An infection-fighting protein molecule in blood that 
attaches to and neutralizes viruses. 
clinical trials—Studies conducted among volunteer participants; 
clinical trials test the safety and efficacy of new drugs. Controlled 
means that some participants actually receive the drug being 
tested while others receive placebo (an inactive substance). 
Randomized means that assignment to a group is random. Double-
blind means that neither participants nor researchers know until 
after the study is completed who was assigned to which group; 
that is, who received the drug being tested and who received 
placebo. 
All new vaccines must pass 3 phases of clinical trials before they 
can be considered for regulatory licensure. 
Phase I—Tests for safety and dosage. 
Phase II—Tests for efficacy and further tests for safety. 
Phase III—Large-scale studies for efficacy. For HIV vaccines,  
 these tests must be performed in thousands of individuals  
 who are HIV-negative but at high risk for HIV. 
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SixWhere	Is	Information	Available?
efficacy—Ability of a drug or product to produce the desired 
outcome under ideal (experimental) conditions, as opposed to 
under average (real-world) conditions.
epidemic—The occurrence in a community or region of cases of an 
illness, specific health-related behavior, or other health-related 
events clearly in excess of normal expectancy.
HAART (highly active antiretroviral therapy)—HIV treatment 
regimens, consisting of combinations of drugs that have been 
shown to reduce the amount of HIV virus in a patient’s blood. 
HIV (human immunodeficiency virus)—The virus that causes 
AIDS. Not all people infected with HIV have AIDS, but all people 
with AIDS are infected with HIV. 
HIV counseling, testing, and referral
counseling—An HIV-prevention intervention. The counseling 
approach used is critical to the success of HIV prevention efforts. 
A client-centered HIV prevention counseling model has been 
shown to be especially effective. This model focuses on helping 
clients identify HIV risk behaviors and commit to personalized 
steps to reduce their HIV-related risks.  
 testing—Laboratory determination of HIV status. Voluntary 
testing can be obtained in medical care settings such as doctors’ 
offices, hospitals, managed care organizations, and public 
health clinics or can be performed using home-collection kits. 
HIV testing may be required as part of screening programs for 
military personnel, blood donors, correctional facility inmates, and 
insurance applicants. 
  anonymous testing—People who choose anonymous HIV 
testing are not required to provide their names; therefore, test 
results are not linked to any records with an identifying name 
(including the request for tests or test results). 
confidential testing—People who choose confidential testing 
provide their names, and testing information is documented in 
their record. 
More about HIV Prevention
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 referral—The process by which immediate client needs for 
medical, prevention, and social support services are assessed, 
prioritized, and addressed (in the context of HIV prevention 
counseling and testing).
incidence—The number of new events, such as HIV infections, over 
time (usually a year).
intervention—An action intended to modify an outcome. Examples 
of HIV prevention interventions include counseling, educational 
messages, and discussion groups intended to help reduce HIV 
transmission.
outreach—Extending services to a wider section of the population 
than are currently receiving the services. 
preclinical trials—Laboratory and animal studies designed to test 
the mechanisms, safety, and efficacy of a drug or medical device 
before, if ever, testing it in people. 
prevalence—The number of people affected by a condition, such as 
HIV infection, at a given point in time. 
surveillance—An ongoing, systematic process of collecting, 
analyzing, interpreting, disseminating, and evaluating data. 
Surveillance data are used to track disease and provide 
information for action to protect the public health. 
 AIDS surveillance—AIDS diagnoses are reported to CDC from 
all US states and territories.
 HIV surveillance—All states have some form of HIV infection 
reporting. As of January 2005, 42 states and territories have 
confidential, name-based HIV reporting systems and forward this 
information to CDC. However, it is not possible to examine trends 
in HIV diagnoses in all 42 states because many have just recently 
begun HIV reporting. Therefore, most of the HIV trends reported 
in this document come from data from 25 states that have 
required HIV reporting since 1993 (longstanding HIV reporting).
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vaccine—A preparation that stimulates the body’s immune system 
to protect itself from an invading virus. 
virus—A microorganism made of either DNA or RNA with a protein 
coat. Viruses invade healthy cells and then use those host cells 
to replicate, spreading disease or infection. HIV, the virus that 
causes AIDS, is particularly dangerous because it attacks the 
body’s immune system cells.
zidovudine—One of the drugs used to treat AIDS. May be 
abbreviated as ZDV or AZT.




The CDC National Prevention Information Network (NPIN)  
Phone 1-800-458-5231 or 1-800-243-7012 (TTY) or go to  
www.cdcnpin.org 
The	following	CDC	publications	can	be	obtained	through	NPIN:	
2002 National Center for HIV, sTD & Tb Prevention Program 
Review
 Also available at www.cdc.gov/nchstp/od/program%20review/
2002%20prog%20rev%20book%20FINAL.htm
Compendium of HIV Prevention Interventions with Evidence of 
Effectiveness
 Also available at www.cdc.gov/hiv/pubs/hivcompendium/
hivcompendium.htm
HIV Counseling and Testing in Publicly Funded sites: Annual 
Report (all years)
 Also available at www.nchstp.cdc.gov/dhap/pubs.htm
HIV Prevention strategic Plan Through 2005
 Also available at www.cdc.gov/nchstp/od/hiv_plan/default.htm
HIV/AIDs surveillance Report (all issues)
 Also available at www.cdc.gov/hiv/stats/hasrlink.htm 
Additional	websites	
www.cdc.gov/hiv 
(CDC’s HIV/AIDS home page)
www.cdc.gov/nchstp/od/nchstp.html  
(CDC’s National Center for HIV, STD, & Tb Prevention)
www.cdc.gov/hiv/dhap.htm  




(listing of all Morbidity and Mortality Weekly Reports [MMWRs])
www.cdc.gov/hiv/pubs/mmwr.htm  
(compilation of all MMWR issues on HIV and AIDS since 1981)
www.effectiveinterventions.org 
(list of science-based HIV prevention interventions that work) 
Guidelines
CDC. Revised guidelines for HIV counseling, testing, and referral. 
MMWR 2001;50(RR-19):1–58. 
Also available at www.cdc.gov/MMWR/preview/MMWRhtml/
rr5019a1.htm
CDC. Revised recommendations for HIV screening of pregnant 
women. MMWR 2001;50(RR-19):59–86. 
Also available at www.cdc.gov/MMWR/preview/MMWRhtml/
rr5019a2.htm
CDC. Guidelines for national human immunodeficiency virus case 
surveillance, including monitoring for human immunodeficiency 
virus infection and acquired immune deficiency syndrome. MMWR 
1999;48(RR-13):1–31.  
Also available at www.cdc.gov/MMWR/preview/MMWRhtml/
rr4813a1.htm
CDC. HIV Partner Counseling and Referral Services. Guidance. 
Atlanta, Georgia: US Department of Health and Human Services, 
CDC. December 1998. 
Also available at www.cdc.gov/HIV/pubs/pcrs.htm
CDC, Health Resources and Services Administration, National 
Institutes of Health, HIV Medicine Association of the Infectious 
Diseases Society of America, and the HIV Prevention in Clinical 
Care Working Group. Incorporating HIV prevention into the  
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medical care of persons living with HIV. MMWR 2003;52(RR-
12):1–24. 
Also available at www.cdc.gov/mmwr/preview/mmwrhtml/
rr5212a1.htm 
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